Company / Working Capital
BeOne Medicines Ltd. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$4.4B
FY2025
5-year range
$1.8B / $6.0B
FY2021-FY2025
Trend
+147.9%
vs FY2024
Sector context
#11 of 213
Health Care
What the data says
Among 213 Health Care companies, BeOne Medicines Ltd. is in the top 5% for working capital. Working Capital returned to growth in FY2025 after 3 years of decline, reaching $4.4B.
Based on SEC 10-K filings.
$4.4B in FY2025 with a 5-year CAGR of +2.5%. Top quartile in the Health Care sector.
Improved from $2.4B to $4.4B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +2.5%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 213This company $4.4B Sector average $934.6M
▼
+371.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.5%, indicating consistent growth.
- In FY2025, working capital increased 147.9% year-over-year.
- Ranks #11 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.4B | +147.9% |
| FY2024 | $1.8B | -25.8% |
| FY2023 | $2.4B | -36.0% |
| FY2022 | $3.7B | -37.8% |
| FY2021 | $6.0B | +54.8% |
| FY2020 | $3.9B | +350.6% |
| FY2019 | $862.4M | -49.2% |
| FY2018 | $1.7B | +122.3% |
| FY2017 | $763.5M | +125.0% |
| FY2016 | $339.3M | +377.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026